CD44 and cancer: Overall, the results pointed out that ANXA5 might aggravate cell proliferation and migration of U251 and SHG44 cells via CD44. The literature indicates that CD44 may participate in malignant behaviors in cancer partially via the MAPK/ERK pathway (21).